# PREDICT-RT (NCT04513717)

> Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04513717
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: NRG Oncology
- Conditions: Prostate Adenocarcinoma; Stage III Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8
- Interventions: Apalutamide; Bicalutamide; Biospecimen Collection; Bone Scan; Buserelin; Computed Tomography; Degarelix; Flutamide; Goserelin; Histrelin; Leuprolide; Magnetic Resonance Elastography; Positron Emission Tomography; Quality-of-Life Assessment; Questionnaire Administration; Radiation Therapy; Relugolix; Triptorelin
- Enrollment: 2753
- Primary outcome: Metastasis-free survival (MFS)
- Primary outcome: Sexual quality of life (De-intensification study)
- Primary outcome: Hormonal quality of life (De-intensification study)
- Primary outcome: Fatigue (Intensification study)

## Indexed commentary on PREDICT-RT so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 9
- Podcasts: 7
- YouTube: 4
- X videos: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=predict-rt-nct04513717

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04513717", "email": "<work email>"}; the inbox owner confirms by the emailed link.